The greater utilization and acceptance of physiologically‐based pharmacokinetic (PBPK)
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …

Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …

This white paper provides a critical analysis of methods for estimating transporter kinetics
and recommendations on proper parameter calculation in various experimental systems …

Membrane transporters play an important role in intestinal absorption, distribution and
clearance of drugs. Additionally transporters along with enzymes regulate tissue exposures …

Unmanageable severe adverse events caused by drug‐drug interactions (DDIs), leading to
market withdrawals or restrictions in the clinical usage, are increasingly avoided with the …

Physiologically based pharmacokinetic modeling is a commonly used strategy in the drug
development and regulatory submissions. This commentary provides a critical overview of …

Introduction: Membrane transporters have been recognized to play a key role in determining
the absorption, distribution and elimination processes of drugs. The organic anion …

Introduction Transporters are significant in dictating drug pharmacokinetics, thus inhibition of
transporter function can alter drug concentrations resulting in drug-drug interactions (DDIs) …

The role of membrane transporters on pharmacokinetics (PKs), drug–drug interactions
(DDIs), pharmacodynamics (PDs), and toxicity of drugs has been broadly recognized …

Abstract Evaluation of drug–drug interaction (DDI) risk is vital to establish benefit–risk
profiles of investigational new drugs during drug development. In vitro experiments are …